VALION BIO INC (VBIO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.77-1.07%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VBIO
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Execute a 1-for-25 reverse stock split to meet Nasdaq minimum bid price requirements and maintain listing compliance.
Stated as a priority in 2 disclosures in 2026. The company received Nasdaq non-compliance notice on March 19, 2026, due to stock price below $1.00 for 30 days. The Board declared a 1-for-25 reverse stock split effective August 31, 2026, to regain compliance. This action aligns with management's stated objective and is delivering on the regulatory priority.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Control net loss to remain within the 2025 guidance range of $8.8 million to $9.1 million.
Stated as a priority in 2 quarters (2026-Q1 and 2026-Q2). The 2025 net loss guidance range is $8.8M to $9.1M, compared to $5.7M in 2024. Actual net losses in early 2026 quarters were -$6.2M and -$7.1M, indicating ongoing losses but within the expected range. The trajectory shows management maintaining focus on loss control consistent with guidance.
“Net income was -$7.1 million in 2026-Q2, reflecting ongoing losses.”
“Net income was -$6.2 million in 2026-Q1, consistent with loss management focus.”
Appoint Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs to strengthen legal leadership.
Newly stated in 2026-Q2 with the appointment of Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs. This leadership change is recent and no financial metrics apply. The priority reflects management's focus on strengthening legal and governance capabilities.
Focus on advancing Entolimod development and expanding government, international, and commercial partnerships.
Newly stated in the 2026-09-01 disclosure with the expanded COO role overseeing Entolimod advancement and partnership expansion. No direct financial metrics are available yet. The priority signals strategic focus on product and market growth.
Grow operational capacity by leasing a new approximately 8,024 sq ft facility to support development and manufacturing.
Over the trailing year it converted 0.82x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
38 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.